Chang, Cheng-YuCheng-YuChangWei, Yu-FengYu-FengWeiCHUNG-YU CHENLai, Yi-ChunYi-ChunLaiHu, Po-WeiPo-WeiHuHung, Jui-ChiJui-ChiHungChu, Chi-HsiangChi-HsiangChuChuang, Hsin-TzuHsin-TzuChuangChang, Shih-ChiehShih-ChiehChang2023-12-082023-12-0820232296-858Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/637612Randomized controlled trials have demonstrated a reduction in the decline of lung function and a reduced risk of acute exacerbation in patients with idiopathic pulmonary fibrosis treated with the antifibrotic prifenidone. The present study aimed to investigate the real-world effectiveness and safety profile of pirfenidone treatment for patients with IPF in Taiwan.enforced vital capacity; idiopathic pulmonary fibrosis; pirfenidone; progression free survival; tumor necrosis factor alphajournal article10.3389/fmed.2023.1242260379648852-s2.0-85176464495https://api.elsevier.com/content/abstract/scopus_id/85176464495